M ethods

Study Population
The study was conducted according to the Declaration of Helsinki and the guidelines for Good Clinical Practice and was approved by our institutional ethics committee. Written informed consent was obtained from the patients or from relatives prior to participation in the study.
Two cohorts of elderly patients were included. The fi rst cohort (development cohort) was included for developing the upper gastrointestinal symptom questionnaire for the elderly population (UGISQUE); the second cohort (validation cohort) was involved in the study to validate the questionnaire in a multicentric population in the frame of the IPOD project ( i dentifi cation of sym p t o ms and risk factors to detect refl ux d isease in elderly populations).
For inclusion in the development cohort, all patients aged 60 years or older who underwent an upper gastrointestinal ( 20 ) ), comorbidity, and drug assumption was collected from all participants.
The UGISQUE
For developing the UGISQUE, an analysis of symptoms in the development cohort population was initially done for identifying the most relevant symptoms that could predict the endoscopic outcome. Symptoms were collected just before the endoscopy; both the patients and the investigators were not aware of the results. Our starting point was the Gastrointestinal Symptom Rating Scale (GSRS), as modifi ed for patients with upper gastrointestinal disorders ( 21 ) . The GSRS questionnaire included eight items (items 1 -8) for the description of upper gastrointestinal symptoms and seven items (items 9 -15) that described diarrhea and constipation; only the fi rst eight items were evaluated in the present study. Other symptoms were recorded when they were indications for performing the endoscopy. In particular, the following symptoms were recorded: hematemesis, melena, anemia defi ned as a loss of 3 g or more of hemoglobin during the past 3 months ( 22 ) , anorexia ( 23 ) , weight loss of 3 kg or more during the past 3 months ( 24 ), vomiting, and dysphagia ( 25 ) . Thus, the UGISQUE included 15 items for the description of symptoms divided into fi ve symptom clusters: (a) abdominal pain syndrome (stomach ache/pain, hunger pains in stomach or belly), (b) refl ux syndrome (heartburn, acid refl ux), (c) indigestion syndrome (nausea, rumbling in the stomach [ie, vibrations or noise in the stomach], bloated stomach [ie, swelling in the stomach], burping [ie, bringing up air or gas through the mouth]), (d) bleeding (hematemesis, melena, anemia), and (e) nonspecifi c symptoms (anorexia, weight loss, vomiting, dysphagia).
The UGISQUE included a response scale with four grades: (a) absent = no symptoms are reported by patient; (b) mild = awareness of symptoms, but they are easily tolerated; (c) moderate = symptoms interfering with the normal activities; and (d) severe = symptoms that induced inability to perform normal activities or symptoms requiring health intervention. Symptomatic patients were defi ned as those who reported moderate or severe discomfort in at least one item.
Endoscopic Diagnoses
At study entry, an endoscopy was performed. Refl ux esophagitis (E) was endoscopically defi ned and classifi ed according to the Los Angeles classifi cation ( 26 ) . Hiatus hernia was diagnosed when the Z-line and the gastric folds extended 2 cm or more above the diaphragmatic hiatus ( 27 ) . Gastric and duodenal lesions were defi ned according to the Cotton and Williams ' criteria ( 28 ) . According to their endoscopic diagnoses, in both cohorts, four groups of individuals were considered: (a) individuals without organic lesions (WOL), (b) individuals with E), (c) individuals with erosive gastritis (EG), and (d) individuals with PU.
Helicobacter pylori infection was studied histologically using the Sydney classifi cation ( 29 ) and by the rapid urease test performed on both gastric antral and body biopsies (CLO test; Delta West, Bentley, Australia). Patients were considered infected with H. pylori if at least one method was positive for the infection; patients were considered not infected if both methods were negative for the infection ( 30 ) .
Statistical Analysis
The association among general characteristics, symptomatology, and groups of individuals was studied using the chi-square test or Fisher exact test. Group mean values were compared through the generalized linear model procedure, after testing for homoschedasticity (Levene ' s test). In case of heteroschedasticity, Welch ' s analysis of variance was performed. The goodness of fi t of prediction models based on the UGISQUE was evaluated defi ning logistic regression models for both development and validation cohorts, with binomial outcomes in relation to endoscopic diagnosis (E vs WOL; EG vs WOL; PU vs WOL; E, EG, or PU vs WOL), adjusting for age and sex. Area under the receiver-operating characteristic curves (ROCs) were compared using Delong ' s test ( 31 ) , and Hanley and McNeil ' s method ( 32 ) .
Power analysis was calculated on ROC curves in both development and validation cohort samples, achieving a power of .98 and .64, respectively.
All statistical analyses were performed using SAS, version 9. Note: BMI = body mass index, E = esophagitis, EG = erosive gastritis, ns = not signifi cant, PU = peptic ulcer, WOL = without organic lesions.
R esults
Development Cohort
Two hundred six patients were included: 89 men and 117 women, mean age = 76.2 ± 7.1 years, range = 62 -96 years. The endoscopic diagnoses were as follows: E = 32 patients (15.5%), EG = 51 patients (24.8%), PU = 54 patients (26.2%), and WOL = 69 patients (33.5%). Characteristics of patients stratifi ed by endoscopic diagnoses are reported in Table 1 . As shown in Figure 1 , patients with E showed signifi cantly more abdominal pain ( p = .0028), refl ux symptoms ( p < .0001), indigestion syndrome ( p = .0004), and nonspecifi c symptoms ( p = .0001) than WOL patients. PU patients demonstrated signifi cantly higher frequency of abdominal pain ( p = .02), bleeding ( p < .0001), and nonspecifi c symptoms ( p < .0001) than WOL patients. Patients with EG had signifi cantly higher frequency of abdominal pain ( p < .02) and nonspecifi c symptoms ( p = .0039) than WOL patients.
The predictive value of UGISQUE was good, with an area under the ROC curve of .80 (95% confi dence interval [CI] 0.743 -0.864) in patients with any pathological feature at endoscopy (E, PU, or EG). The accuracy of UGISQUE was signifi cantly higher in patients with E (ROC area = .87, 95% CI 0.80 -0.94) and in patients with PU (ROC area = .87, 95% CI 0.81 -0.93) than in patients with EG (ROC area = .74, 95% CI 0.65 -0.83; E vs EG, p = .001 and PU vs EG, p = .0008). Moreover, using the Delong ' s test, we found that UGISQUE had signifi cantly higher diagnostic accuracy than the individual clusters of symptoms in predicting the presence of E ( p = .004), PU ( p < .0001), or any pathological condition (E, PU, or EG, p < .0001) as diagnosed by endoscopy.
Validation Cohort
The validation cohort included 326 patients: 169 men and 157 women, mean age = 72.0 ± 7.2 years, range = 60 -93 years ( Table 1 ) . The endoscopic diagnoses were as follows: E = 96 patients (29.4%), EG = 81 patients (24.8%), PU = 48 patients (14.7%), and WOL = 101 patients (31.0%). As shown in Figure 1 , patients with E showed signifi cantly more abdominal pain ( p = .0009), refl ux symptoms ( p < .0001), indigestion syndrome ( p < .0001), bleeding ( p = .04), and nonspecifi c symptoms ( p = .05) than WOL patients. Patients with PU had more abdominal pain ( p = .02), refl ux symptoms ( p = .006), bleeding ( p < .0001), and nonspecifi c symptoms ( p = .0003) than WOL patients. Finally, patients with EG had signifi cantly more abdominal pain ( p = .002), bleeding ( p = .0002), and nonspecifi c symptoms ( p = .0229) than WOL patients. The area under the ROC curve of UGISQUE in patients with any pathological condition at endoscopy (E, EG, or PU) was also good (ROC area = .78, 95% CI 0.73 -0.83). Diagnostic accuracy of UGISQUE was higher in patients with E (ROC area = .86, 95% CI 0.81 -0.91) and with PU (ROC area = .78, 95% CI 0.70 -0.86) than in those with EG (ROC area = .73, 95% CI 0.66 -0.80; E vs EG, p < .0001 and PU vs EG, p = not signifi cant).
As observed in the development cohort, also in the validation cohort UGISQUE had signifi cantly higher diagnostic accuracy than the individual clusters of symptoms in predicting the presence of E ( p = .0001), PU ( p < .0001), or any pathological condition (E, PU, or EG, p < .0001).
D iscussion
The study reports the development and validation of a new questionnaire for the evaluation of symptoms in two independent cohorts of elderly individuals with endoscopic diagnoses of E, PU, or EG. The fi ndings of the study demonstrated that elderly patients with gastrointestinal disorders had signifi cantly higher rates of abdominal pain, refl ux symptoms, indigestion syndrome, bleeding, and also nonspecifi c symptoms, than those without endoscopic lesions. Because the presence of nonspecifi c symptoms has been reported as one of the most important reasons for late diagnoses ( 1 ) or even severe complications ( 3 ) in elderly patients, the fi ndings of the study support the concept that the use of a comprehensive diagnostic tool specifi cally developed for elderly patients may be useful in reducing misleading and underrecognized diagnoses.
The heterogeneity of symptoms reported by the patients of both the cohorts indirectly confi rms that the elderly patient may have a different clinical expression of the upper gastrointestinal diseases compared with young or adult individuals ( 1 , 2 ) .
The predictive value of UGISQUE in identifying older patients with upper gastrointestinal disorders was good in both the cohorts. Moreover, the diagnostic accuracy of UGISQUE was higher in patients with E and PU than in patients with EG. Indeed, the analysis of clinical characteristics of patients with different pathologies failed to fi nd any signifi cant role of comorbidities, drug use, or functional disability that may explain these discrepancies.
To our knowledge, this is the fi rst diagnostic questionnaire for the evaluation of upper gastrointestinal disorders specifi cally developed for and validated in elderly patients. The different physicians involved in the study did not encounter problems with the administration of the UGISQUE or with the collection of data. Moreover, no signifi cant problems were reported by the patients in the understanding of the questionnaire or by the investigators in the evaluation of responses.
The study has some limitations. Because UGISQUE was developed and validated in elderly patients who underwent an upper gastrointestinal endoscopy in selected centers, it is likely that the instrument may not be so accurate for the evaluation of elderly patients from different settings. Moreover, the absence of assessment of lower gastrointestinal symptoms as well as of reliability and validity of individual items may limit the clinical usefulness of the UGISQUE. Finally, all patients who were in treatment with antisecretory drugs were excluded; because it has been reported that these treatments may signifi cantly infl uence the symptomatology in older patients with upper gastrointestinal disorders ( 33 , 34 ) , we cannot exclude the fact that a specifi c validation of UGISQUE is needed in these patients.
In conclusion, we developed and validated a new questionnaire for the evaluation of elderly patients with upper gastrointestinal disorders. Further studies are needed to explore its effi cacy and clinical usefulness in clinical trials.
